Venture Madness Alumni Presentation
Transforming Tubulin Therapy
for Brain Diseases
Novel Therapeutics Are Lacking for Brain Cancer and Brain Diseases
Reglagene's lead program is a novel, orally administered, well-tolerated, blood–brain barrier penetrant therapy for the treatment of brain cancers.
Reglagene's product pipeline also includes disease indications driven by brain inflammation.
Reglagene Is Developing Novel Therapies for Diseases with High Unmet Medical Need
Current cancer therapies are highly toxic. Most therapies are given intravenously and cause many unwanted side effects. It is important to the Reglagene team to develop orally available, well-tolerated medicines for patients to use in the comfort of their own homes.
Reglagene's first therapy attacks a highly validated cancer target, previously inaccessible in brain cancer owing to the BBB. Many therapies and drug-delivery systems have tried and failed to access this target in brain. Reglagene has found a way to make this possible.
BLOOD–BRAIN BARRIER (BBB) PENETRANT
Only 2% of all marketable drugs can cross the BBB, a filter that prevents toxins and medicines from entering the brain. Reglagene’s brain cancer therapy crosses the BBB and has nearly the same concentration in peripheral blood as in the brain.
MEDICINES FOR A GLOBAL MARKET
Reglagene accesses the advantages of what are known as small-molecule medicines. Benefits of small molecule medicines include: oral administration, low manufacturing costs, and well-traveled development and regulatory pathways.
3320 N Campbell Ave, Suite 200 | Tucson, AZ 85719 | USA